Bachrodt Amy has officially filed a Form 3 with the SEC, confirming her position as Chief Financial Officer at Lycia Therapeutics, Inc. This filing is significant as it outlines her role and stock options within the company, shedding light on her influence in the biological products industry.
Lycia Therapeutics, Inc. specializes in biological products, a sector that focuses on developing therapies derived from living organisms. The company is incorporated in Delaware and operates from South San Francisco, CA. The filing, dated October 22, 2026, is part of the company's ongoing compliance with SEC regulations.
The filing indicates that Bachrodt has no securities currently owned but holds stock options for 399,746 shares of common stock, with an exercise price of $3.70. These options will vest over time, with a quarter of the total award vesting on June 2, 2027, and the remainder vesting monthly thereafter. This structured vesting schedule links her compensation to her continued service at the company.
As Chief Financial Officer, Bachrodt's actions and decisions may significantly impact Lycia Therapeutics, especially in financial strategy and investor relations. The company operates in a competitive landscape, and her role could influence how the market perceives its financial health and growth potential.
The filing does not specify what will happen next, but it does highlight Bachrodt's ongoing responsibilities and the importance of her position within the company.